Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Bayer AG BAYRY announced that the first patient has been enrolled in the late-stage SOHO-02 study on pipeline candidate BAY ...

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Biohaven Ltd. (BHVN – Research Report). The associated price ...

Dermacyte Liquid, a first-in-class biologic, offers a promising new solution to help close ... and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid) has not ...

Obtaining an investigational drug through an EAP can be complex and ... pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

Dato-DXd is an engineered TROP2-directed DXd antibody-drug conjugate discovered by Daiichi Sankyo Ltd DSKYF DSNKY and being jointly developed by AstraZeneca and Daiichi Sankyo. In the overall ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.